Reduce risk of bone fracture

Reduce risk of bone fracture with Preotact®

Osteoporosis patients experience low bone mass, structural deterioration of bone and increased risk of bone fracture. Due to the risk of bone fracture osteoporosis can affect life expectancy and quality of life. Preotact® can reduce risk of bone fracture by increasing bone mineral density, which improves bone microarchitecture and restores bone quality and quantity.

Preotact® is a full-length parathyroid hormone therapy for postmenopausal osteoporosis patients that can reduce risk of bone fracture. Studies have demonstrated that patients treated with Preotact® had a 61 % relative risk reduction of a new vertebral bone fracture.

Log in to learn more about how to reduce risk of bone fracture

Nycomed

Nycomed is a European pharmaceutical company that has over 20 years’ experience of working with osteoporosis. Nycomed operates throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Offering a broad portfolio of products in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.